---
title: "Immunic | 10-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277038956.md"
datetime: "2026-02-26T12:19:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277038956.md)
  - [en](https://longbridge.com/en/news/277038956.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277038956.md)
---

# Immunic | 10-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -0.62.

EBIT: As of FY2025, the actual value is USD -104.27 M.

#### Net Loss

Immunic, Inc. reported a net loss of - $97.2 million for the year ended December 31, 2025, a decrease from - $100.5 million for the year ended December 31, 2024, representing a $3.3 million or -3% reduction in net loss. The accumulated deficit as of December 31, 2025, was - $608.6 million, an increase from - $511.4 million as of December 31, 2024.

#### Operating Expenses

-   **Research and development expenses** increased by $1.9 million (2%) to $82.0 million in 2025 from $80.0 million in 2024. This was primarily due to a $3.9 million rise in external development costs for the vidofludimus calcium program and a $1.8 million increase in personnel expenses for R&D, partially offset by a - $3.0 million decrease in external development costs for the IMU-856 program.
-   **General and administrative expenses** increased by $3.2 million (18%) to $21.2 million in 2025 from $18.0 million in 2024, mainly driven by a $1.9 million increase in personnel expenses (including $0.3 million non-cash stock compensation) and a $0.8 million increase in legal and consultancy expenses.
-   **Total operating expenses** for 2025 were $103.2 million, up from $98.1 million in 2024, an increase of $5.2 million (5%).

#### Other Income (Expense), Net

-   **Interest income** decreased by - $2.4 million (-69%) to $1.0 million in 2025 from $3.4 million in 2024, attributed to a lower average cash balance.
-   **Change in fair value of tranche rights** was $0 in 2025, compared to - $4.8 million in 2024.
-   **Other income (expense), net** increased by $6.1 million (-578%) to $5.0 million in 2025 from - $1.0 million in 2024. This was primarily due to $4.8 million in grant income from the German Federal Ministry of Finance and a - $1.7 million expense related to deal costs from the January 2024 Financing in 2024, partially offset by a - $0.7 million decrease in Australian R&D tax incentives.

#### Cash Flows and Liquidity

-   **Net cash used in operating activities** was - $85.8 million in 2025, compared to - $84.8 million in 2024.
-   **Net cash used in investing activities** was - $0.2 million in 2025, compared to - $0.3 million in 2024.
-   **Net cash provided by financing activities** was $65.6 million in 2025, compared to $74.5 million in 2024.
-   **Cash and cash equivalents** stood at $15.5 million as of December 31, 2025, down from $35.7 million as of December 31, 2024.
-   From inception through December 31, 2025, Immunic, Inc. raised approximately $496.3 million in net cash from various offerings.
-   A private placement closed on February 17, 2026, generating net cash proceeds of approximately $187.0 million.

#### Outlook / Guidance

Immunic, Inc. expects to fund its operations beyond twelve months from the date of the issuance of the accompanying consolidated financial statements, leveraging the net proceeds from the February 2026 private placement. The company anticipates continued significant expenses and increasing operating losses in the foreseeable future as it advances its clinical pipeline and prepares for potential commercialization of vidofludimus calcium. Immunic, Inc. also has $262.2 million remaining under its 2023 Shelf Registration Statement and $80.0 million in capacity under its May 2024 At-The-Market Sales Agreement as of December 31, 2025.

### Related Stocks

- [IMUX.US](https://longbridge.com/en/quote/IMUX.US.md)

## Related News & Research

- [SemiLEDs Reports Second Quarter Fiscal Year 2026 Financial Results | LEDS Stock News](https://longbridge.com/en/news/282650581.md)
- [CarMax Q4 revenue beats on higher wholesale unit volume](https://longbridge.com/en/news/282677678.md)
- [Pineapple Financial Reports Fiscal Q2 2026 Financial Results and Provides Digital Asset Treasury Update | PAPL Stock News](https://longbridge.com/en/news/282587469.md)
- [Zacks Research Has Positive Estimate for KBR FY2028 Earnings](https://longbridge.com/en/news/282670727.md)
- [TCS makes 25,000 fresher offers in FY27, more hiring depends on demand: CEO](https://longbridge.com/en/news/282436594.md)